FDA Advisory Committees Would Get Patient Influence Under Hagan Bill
This article was originally published in The Tan Sheet
Executive Summary
Adjusting advisory committee conflict of interest rules becomes a high-priority issue in reauthorizing FDA’s drug user fee program. With several bills proposing to loosen the rules, Sen. Hagan’s draft FDA reform legislation could bring the most changes.
You may also be interested in...
Flurries Of New Bills Advance Device Industry Interests In Congress
The first legislative salvos were launched last week in a battle that is sure to escalate in conjunction with device user fee reauthorization efforts next year.
Advisory Committee Vacancies Remain High As FDA Revs Up Search
With its recent hiring push drawing attention, FDA is quietly undertaking another recruitment effort - filling advisory committee roster vacancies
A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: